Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
Clinical trial NCT00448864 · TERMINATED
Trial details
- NCT number
- NCT00448864
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-05-01
- Primary completion
- 2008-07-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.